Clinical Trial Update: Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the safety and efficacy of an allogeneic cell therapy for intermittent claudication; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intermittent Claudication
• Peripheral Artery Disease

Drugs mentioned

• Allogeneic cell therapy product

Snippet

Sponsor: Pluristem Ltd. | Conditions: Intermittent Claudication, Peripheral Artery Disease | Phase 2 | Status: COMPLETED